Honokiol Inhibits Atrial Metabolic Remodeling in Atrial Fibrillation Through Sirt3 Pathway

Guang Zhong Liu1,2, Wei Xu3, Yan Xiang Zang3

  • 1Department of Cardiology, Shenzhen Cardiovascular Minimally Invasive Medical Engineering Technology Research and Development Center, Shenzhen People's Hospital, Shenzhen, China.

Insights

Honokiol (HL) reversed atrial metabolic remodeling in atrial fibrillation (AF) by activating Sirtuin3 (Sirt3). This study suggests HL as a potential therapeutic strategy for AF by restoring energy homeostasis.

Area of Science:

  • Cardiovascular Research
  • Metabolic Pathways
  • Molecular Biology

Background:

  • Atrial metabolic remodeling is a key factor in atrial fibrillation (AF) development.
  • Sirtuin3 (Sirt3) is crucial for maintaining cellular energy balance.
  • The therapeutic potential of the Sirtuin3 agonist Honokiol (HL) in AF remains largely unexplored.

Purpose of the Study:

  • To investigate the impact of Honokiol (HL) on atrial metabolic remodeling in the context of atrial fibrillation (AF).
  • To elucidate the underlying mechanisms by which HL influences AF pathophysiology, particularly concerning Sirtuin3 (Sirt3) activity.

Main Methods:

  • Analysis of Sirt3 and glycogen in atrial tissues from AF patients and a rabbit pacing model.
  • In vitro experiments using HL-1 cells subjected to rapid pacing, with or without HL treatment and Sirt3 modulation.
  • Assessment of metabolic factors, circulating metabolites, atrial electrophysiology, ATP levels, glycogen deposition, and protein acetylation.

Main Results:

  • Sirt3 was downregulated in AF, and HL treatment restored its expression and downstream metabolic factors.
  • AF increased acetylation of key metabolic enzymes (LCAD, AceCS2, GDH), reducing their activity and ATP levels; HL inhibited these effects.
  • Sirt3 activation by HL mitigated AF-induced atrial metabolic remodeling and restored metabolic homeostasis.

Conclusions:

  • Honokiol (HL) effectively inhibits atrial metabolic remodeling in AF through the Sirtuin3 (Sirt3) pathway.
  • HL demonstrates potential as a novel therapeutic agent for managing atrial fibrillation (AF).

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
540
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
54
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
76
Regulation of Heart Rates01:31

Regulation of Heart Rates

The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
2.4K
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
1.1K